Clinical Trials Sponsored by FORUM Pharmaceuticals Inc

Total 16 results

A. Eden Evins

Terminated

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

Smoking Cessation | Nicotine Dependence

United States
FORUM Pharmaceuticals Inc

Terminated

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Dementia | Alzheimer's Disease

United States, France, Poland, Spain, Belgium, South Africa, Korea, Republic of, Canada, Germany, Italy, Mexico, Australia
FORUM Pharmaceuticals Inc

Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Australia, Poland, Ukraine, Germany, Spain, Argentina, Serbia, Canada, Singapore, Russian Federation, Brazil, Mexico
FORUM Pharmaceuticals Inc

Completed

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Ukraine, United Kingdom, Germany, Spain, Argentina, Canada, Singapore, Russian Federation, Italy, Mexico, Colombia, Australia, Belgium, Poland and more
FORUM Pharmaceuticals Inc

Terminated

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

Dementia | Alzheimer's Disease

United States, United Kingdom, Spain, Canada, Netherlands, Korea, Republic of, Belgium, Poland, South Africa, Czech Republic, Australia, Italy
FORUM Pharmaceuticals Inc

Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Ukraine, United Kingdom, Poland, Romania, Russian Federation, Italy, Mexico, Colombia, Argentina, Australia, Brazil
FORUM Pharmaceuticals Inc

Terminated

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Dementia | Alzheimer's Disease

United States, France, United Kingdom, Spain, Argentina, Canada, Netherlands, Korea, Republic of, Australia, Czech Republic, Germany, Italy, Mexico, South Africa
FORUM Pharmaceuticals Inc

Unknown

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Granulin Mutation

Belgium, United States, France, Italy, Netherlands, United Kingdom
FORUM Pharmaceuticals Inc

Completed

EVP-6124 Renal Impairment Study

Renal Impairment

Czech Republic, Hungary
FORUM Pharmaceuticals Inc

Completed

EVP-6124 Hepatic Impairment Study

Hepatic Impairment

Czech Republic, Poland, Slovakia
FORUM Pharmaceuticals Inc

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

Schizophrenia

United States
FORUM Pharmaceuticals Inc

Completed

Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308

Healthy

United States
FORUM Pharmaceuticals Inc

Completed

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Central Nervous System Diseases | Schizophrenia | Cognition

United States, Russian Federation, Ukraine, Serbia
FORUM Pharmaceuticals Inc

Completed

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Mild Cognitive Impairment | Alzheimer's Disease

United States
FORUM Pharmaceuticals Inc

Completed

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

Central Nervous System Diseases | Schizophrenia | Schizoaffective Disorder

United States
FORUM Pharmaceuticals Inc

Completed

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Central Nervous System Diseases | Alzheimer's Disease

United States

Clinical Trials Sponsored by FORUM Pharmaceuticals Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations